Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment
Our study provides rationale for ICI rechallenge among ES-SCLC patients with <4 metastatic sites, suggesting beneficial outcome by reshaping TME.
Authors
- Kaiyue Guo (ORCID: https://orcid.org/0000-0002-4544-8971)
- Yuanyuan Lv (ORCID: https://orcid.org/0000-0002-4397-8768)
- Xiaoling Shang (ORCID: https://orcid.org/0000-0001-7031-6113)
- Haiyong Wang (ORCID: https://orcid.org/0000-0002-0658-4479)
- Chenyue Zhang (ORCID: https://orcid.org/0000-0001-9130-8374)
- Huijuan Li (ORCID: https://orcid.org/0000-0002-5542-9950)
- Xiaoxiao Zhang (ORCID: https://orcid.org/0000-0003-2157-8744)
Institutions
- Fudan University Shanghai Cancer Center (CN)
- Shandong Tumor Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/itt.s483093
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China
- Shandong First Medical University